Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Chong-Rui Xu, Yan Zhang, Guinan Lin, Haiyong Wang, Qiming Wang, Dingzhi Huang, Yan Yu, Jin Zhou, Hua Zhong, Lin Wu, Lingxiang Liu, Jianchun Duan, Zhiyi He, Yongzhong Luo, Hongxu Liu, Bi Chen, Xinmin Yu, Feng Xue, Qian Chu, Sanxing Guo, Runxiang Yang, Jia Zhong, Haifeng Liu, Longhua Sun, Xiaorong Dong, Haichuan Su, Peng Zhang, Bin Yang, Sisi He, Yuanyuan Ji, Lixin Wan, Xinghua Han, Jingyu Zhang, Fei Qiu, Lulu Yang, Wei Shi, Yi-Long Wu, HERON-Lung01 Investigators

DOI: 10.1016/s0140-6736(26)01899-4

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.